1 4

Biotinylated GPRC5D Flag,His,Avi Tag Full Length Protein, Human(Detergent)

Biotinylated GPRC5D Flag,His,Avi Tag Full Length Protein, Human(Detergent)

Catalog Number: UA060044 Brand: UA BIOSCIENCE
Share:
Price:
$1,325 USD
$1,325 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Species Human
Accession Q9NZD1-2
Amino Acid Sequence

Tyr2–Cys300 with N-terminal Flag and His tags and a C-terminal Avi tag.
Expression System HEK293
Molecular Weight

35~40 kDa (Reducing)
Purity ＞85% by SDS-PAGE
Conjugation Biotin
Tag Avi Tag, His Tag, Flag Tag
Physical Appearance Liquid
Storage Buffer

25 mM Hepes, pH7.5, 150 mM NaCl, 0.0045%LMNG, 0.0015%GDN
Stability & Storage

Stable for 3 months upon stored at -80℃ from the date of receipt. And avoid repeated freeze-thaws cycles.
Reference

1. Jeong, J., et al. (2024). Structural basis for the recognition of GPRC5D by talquetamab, a bispecific antibody for multiple myeloma. Journal of Molecular Biology, 436(20), 168748.
2. Smith, E. L., et al. (2019). GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci. Transl. Med. 11, eaau7746.
3. Yan, P., et al. (2024). The binding mechanism of an anti-multiple myeloma antibody to the human GPRC5D homodimer. Nature communications, 15(1), 5255.

Background

GPRC5D (G protein-coupled receptor class C group 5 member D) is an orphan Class C GPCR encoded by the GPRC5D gene on chromosome 12p13. The core transmembrane protein comprises ~308 residues, featuring a short N-terminal extracellular region (20–50 aa) and lacking the large Venus flytrap domain typical of classical Class C GPCRs.

Structurally, it forms a symmetric homodimer via TM4-TM4/5 interfaces, stabilized by cholesterol molecules. It has an unusually short ECL2, creating an exposed shallow extracellular pocket, and displays weak constitutive Gi/o activity in an inactive-like conformation.

GPRC5D is highly and specifically overexpressed on malignant plasma cells in multiple myeloma (MM), with expression independent of BCMA. High GPRC5D levels correlate with shorter progression-free survival.

Therapeutically, Talquetamab (FDA-approved bispecific GPRC5D/CD3 T-cell engager) and GPRC5D-targeted CAR-T cells have shown potent preclinical/clinical activity, with no significant on-target/off-tumor toxicity. Additionally, LM-305, a GPRC5D-targeting ADC developed by LaNova Medicines (licensed to AstraZeneca), is in Phase I/II trials for relapsed/refractory MM.

Picture

SDS-PAGE

2μg (R: reducing condition).

ELISA

Immobilized Biotinylated GPRC5D Flag,His,Avi Tag Full Length Protein, Human(Detergent) (Cat. No. UA060044) at 1 μg/mL (100 μL/well) on streptavidin precoated (0.5 μg/well) plate can bind Anti-GPRC5D Antibody (LM-305 antibody) with a linear range of 0.41-0.52 ng/mL.

Immobilized Anti-GPRC5D Antibody (LM-305 antibody) at 5 μg/mL (100 μL/well) can bind Biotinylated GPRC5D Flag,His,Avi Tag Full Length Protein, Human(Detergent) (Cat. No. UA060044) with a linear range of 12-17 ng/mL.

Immobilized Biotinylated GPRC5D Flag,His,Avi Tag Full Length Protein, Human(Detergent) (Cat. No. UA060044) at 1 μg/mL (100 μL/well) on streptavidin precoated (0.5 μg/well) plate can bind vemzatatug with a linear range of 1-1.3 ng/mL

Immobilized vemzatatug at 5 μg/mL (100 μL/well) can bind Biotinylated GPRC5D Flag,His,Avi Tag Full Length Protein, Human(Detergent) (Cat. No. UA060044) with a linear range of 11-22 ng/mL.